Stroke Prevention & Brain Health Management | Dr. Ding Ding (Neurology) | CMCS Shanghai

About Dr. Ding Ding

Dr. Ding Ding is a senior neurologist at Huashan Hospital, Fudan University, specializing in cerebrovascular disease, stroke prevention, and cognitive decline. She leads one of Shanghai's most active neurology research programs focused on aging and dementia. Dr. Ding is highly regarded for her evidence-based approach to long-term brain health management in international patients, and her team's work on cerebral small vessel disease is supported by China's National Key Research and Development Programme.

Case Overview

Mr. Robert Chen (pseudonym), a 58-year-old American finance executive serving as Asia-Pacific President of a multinational firm, presented to Huashan Hospital's International Medical Centre with one year of progressive memory decline and episodic leg weakness. His vascular risk profile was severe: uncontrolled hypertension for 10 years, type 2 diabetes, hyperhomocysteinaemia, a father who died of cerebral infarction, and a mother with Alzheimer's disease. Dr. Ding Ding initiated a precision brain health assessment protocol rather than a symptomatic diagnosis. Multimodal 3.0T MRI revealed severe white matter hyperintensities (Fazekas grade 3), multiple cerebral microbleeds on SWI, and disrupted white matter tract integrity on DTI. Plasma biomarkers showed mildly elevated p-tau181/Aβ42 ratio, indicating co-existing Alzheimer's pathology. Diagnosis: vascular cognitive impairment — non-dementia (VCI-ND); severe cerebral small vessel disease (CSVD); high-risk Framingham stroke score (18%). A three-pillar precision intervention programme — vascular-targeted pharmacotherapy, computerised cognitive training, and brain health monitoring — restored MoCA from 22 to 25 at 3 months and reduced plasma NfL by 20%. At month 8, Mr. Chen suffered an acute ischaemic stroke (left MCA occlusion, wake-up onset); Dr. Ding's team performed emergency mechanical thrombectomy guided by CT perfusion imaging, achieving mTICI grade 3 recanalization. Motor strength recovered to grade 4 at 24 hours; modified Rankin Scale score 1 at discharge.

Patient Background

• Age / Nationality: 58-year-old American male
• Occupation: Asia-Pacific President, multinational financial corporation — high-pressure role; chronic sleep deprivation; sedentary lifestyle
• Chief Complaint: Progressive memory decline for 1 year (particularly recent memory — forgetting meeting content); episodic leg weakness on walking
• Vascular Risk Factors: Hypertension (10 years, poorly controlled); type 2 diabetes (5 years); hyperhomocysteinaemia
• Family History: Father died of cerebral infarction; mother diagnosed with Alzheimer's disease
• Lifestyle: Chronic high-stress work environment; insufficient sleep; minimal physical activity

Clinical Assessment & Diagnosis

Rather than reaching a symptomatic conclusion from the presenting complaint alone, Dr. Ding Ding initiated a structured precision brain health assessment protocol — a systematic multi-modal evaluation designed to characterise the nature, severity, and aetiology of cognitive change before any treatment decision was made.

Neuropsychological Testing

• MoCA (Montreal Cognitive Assessment): 22/30 (below normal threshold of 26); primary deficits in delayed recall and executive function
• Fazekas Scale: Applied to quantify white matter lesion burden on MRI

Multimodal MRI (3.0T)

• T2/FLAIR: Extensive bilateral periventricular and deep white matter hyperintensities (WMH); Fazekas grade 3 (severe)
• SWI (Susceptibility-Weighted Imaging): Multiple cerebral microbleeds (CMBs) in the brainstem and basal ganglia — consistent with hypertensive angiopathy
• DTI (Diffusion Tensor Imaging): Reduced fractional anisotropy (FA) values indicating white matter tract integrity disruption, particularly in parahippocampal connectivity — the neural substrate of episodic memory

Plasma Biomarkers

• p-tau181 / Aβ42 ratio: Mildly elevated — indicating co-existing Alzheimer's disease pathological changes superimposed on the dominant vascular injury pattern

Diagnosis

• Primary: Vascular cognitive impairment — non-dementia (VCI-ND)
• Structural: Cerebral small vessel disease (CSVD) with severe white matter hyperintensities and cerebral microbleeds
• Stroke Risk: Framingham Stroke Risk Score 18% (high risk)

Dr. Ding's diagnostic note: "This is a classic 'double hit' — vascular injury compounded by Alzheimer's pathological changes. Both mechanisms must be addressed simultaneously. Treating only the blood pressure and waiting for further deterioration is not a strategy. It is a missed opportunity."

Clinical Decision Making & Intervention Strategy

Conventional approach: Blood pressure and glucose control; watchful waiting until symptoms worsen before initiating pharmacotherapy.

Dr. Ding Ding's evidence-based strategy: "For high-risk individuals in the pre-dementia stage, risk factor control alone is insufficient to halt cognitive decline. We need to apply the latest CSVD-targeted treatment evidence and intervene intensively — before the window of neuroplasticity closes."

Three-Pillar Precision Intervention Programme

Pillar 1 — Vascular-Targeted Pharmacotherapy

• Antiplatelet therapy: Ticagrelor initiated (based on CHANCE-2 subgroup analysis); given fewer than 5 microbleeds and no major haemorrhage history, the benefit-risk balance favoured antiplatelet therapy
• Lipid management: Atorvastatin 20 mg — based on SPARCL trial subgroup data demonstrating stroke risk reduction and potential white matter lesion stabilisation
• Blood pressure target: <130/80 mmHg; ARB-class agent (valsartan) selected as first-line — evidence supports additional cognitive benefit beyond blood pressure reduction in CSVD patients
• Homocysteine reduction: Folate and B-vitamin supplementation to address hyperhomocysteinaemia — an independent modifiable risk factor for white matter progression

Pillar 2 — Cognitive Rehabilitation (Non-Pharmacological)

• Computerised cognitive training: Dr. Ding's team-developed system targeting executive function and working memory; 30 minutes daily protocol
• Dietary prescription: MIND diet (Mediterranean-DASH Intervention for Neurodegenerative Delay) — Dr. Ding's centre data show a 30% reduction in cognitive decline rate in adherent patients
• Lifestyle modification: Structured sleep hygiene programme; aerobic exercise prescription (150 minutes per week moderate intensity)

Pillar 3 — Dynamic Brain Health Monitoring

• Personal brain health record established; plasma NfL (neurofilament light chain — a marker of ongoing neuronal injury) measured at baseline and every 3 months
• MRI surveillance protocol: WMH volume quantification and microbleed count at 6-month intervals

Follow-up & Dynamic Management

3-Month Assessment

• Patient-reported: "My mind feels clearer — I no longer miss details in meetings"
• MoCA: Improved from 22 to 25 (borderline normal)
• Plasma NfL: 20% reduction from baseline — indicating arrest of active neuronal injury
• MRI: WMH volume stable (no increase); microbleed count unchanged — the primary structural success criteria

6-Month Assessment

• Body weight reduced by 5 kg; blood glucose and blood pressure at target
• DTI follow-up: Partial recovery of FA values in previously disrupted white matter tracts — evidence of neuroplasticity and structural brain recovery
• Patient resumed full high-intensity work schedule; leg weakness episodes resolved

Acute Stroke Event — Month 8

At month 8 of the intervention programme, Mr. Chen woke with right-sided limb weakness and dysarthria — FAST criteria positive. Dr. Ding Ding's stroke centre team was activated immediately.

Emergency Response — Stroke Green Channel

• Pre-hospital: Huashan Hospital Stroke Centre app activated; ambulance routed directly to the CT suite, bypassing the emergency department — eliminating triage delay
• Door-to-imaging: One-stop CT perfusion (CTP) completed within 20 minutes of arrival

Imaging Decision

• CTP findings: Left middle cerebral artery (MCA) occlusion; ischaemic penumbra volume significantly exceeds core infarct volume (mismatch ratio >1.5) — large volume of salvageable brain tissue identified
• Wake-up stroke challenge: Onset time unknown (patient woke with symptoms); conventional time-window criteria not applicable
• Decision: Based on perfusion imaging demonstrating salvageable penumbra — not clock time — Dr. Ding proceeded with mechanical thrombectomy. This reflects the paradigm shift from time-based to tissue-based treatment selection in modern stroke care.

Thrombectomy & Outcome

• Recanalization: mTICI grade 3 (complete recanalization) achieved
• 24-hour motor recovery: Right limb strength grade 4/5
• Discharge mRS: 1 (no significant disability; able to carry out all usual activities)

Dr. Ding's note: "For thrombectomy, time is brain — but through multimodal imaging (CTP/DWI-FLAIR mismatch), we can extend the treatment window from 6 hours to 24 hours or beyond. This requires seamless coordination between neurology, radiology, and interventional teams. The infrastructure exists at Huashan. The outcome speaks for itself."

Expert Commentary — Dr. Ding Ding

1. Cerebral Small Vessel Disease: The Silent Killer

CSVD is the leading cause of vascular dementia and gait disorder, and it frequently co-exists with Alzheimer's pathology in a compounding "double hit" pattern. For decades, we lacked the tools to quantify it precisely or intervene effectively. Today, microbleed assessment by SWI, white matter hyperintensity volumetry, and DTI tractography allow us to stratify risk with precision and monitor treatment response objectively. For patients like Mr. Chen, intensified statin and antiplatelet therapy based on CSVD-specific trial evidence — not generic cardiovascular guidelines — can meaningfully slow white matter progression. The evidence exists. The question is whether the clinician knows how to apply it.

2. Whole-Journey Brain Health Management

For international patients, we do not simply prescribe medication. We prescribe a lifestyle. Cognitive training adherence, MIND diet compliance, sleep quality, and aerobic exercise volume are not soft recommendations — they are the primary determinants of long-term cognitive trajectory. Our centre's data show that patients who adhere to the MIND diet reduce their rate of cognitive decline by 30% compared to those who do not. The pharmacotherapy stabilises the vascular substrate. The lifestyle intervention rebuilds the cognitive reserve. Both are required.

3. Biomarkers: The Future Is Now

Plasma p-tau181 and neurofilament light chain (NfL) are not research tools — they are clinical instruments. NfL allows us to detect active neuronal injury before MRI shows visible atrophy, enabling intervention at a stage when neuroplasticity is still intact. p-tau181 identifies co-existing Alzheimer's pathology that would otherwise be invisible on structural imaging. These biomarkers are the foundation of our National Key Research and Development Programme on early dementia intervention. In Mr. Chen's case, the 20% reduction in plasma NfL at 3 months was the earliest objective evidence that our intervention was working — before any MRI change was detectable.

4. Extending the Stroke Treatment Window

The historical 6-hour thrombectomy window was defined by the limits of our imaging technology, not by the biology of ischaemia. Multimodal perfusion imaging — CTP and DWI-FLAIR mismatch — allows us to identify salvageable penumbra regardless of clock time. In wake-up strokes, where onset time is unknown, this is not a theoretical advantage. It is the only basis for treatment. Mr. Chen's complete recanalization and mRS 1 outcome at 24 hours were possible because the decision was made on tissue viability, not on a clock. That is what modern stroke medicine looks like.

How CMCS Shanghai Coordinated This Case

China Medical Concierge Shanghai (CMCS) supported Mr. Chen's care pathway from initial overseas inquiry through ongoing brain health management. Our coordination included:

• Pre-arrival cognitive complaint triage and specialist referral to Dr. Ding Ding's neurology team at Huashan Hospital International Medical Centre — specifically for precision brain health assessment rather than standard outpatient neurology
• Arrangement of multimodal 3.0T MRI (T2/FLAIR, SWI, DTI), neuropsychological testing battery, and plasma biomarker panel (p-tau181, Aβ42, NfL)
• Bilingual interpretation during the diagnostic consultation, including detailed explanation of CSVD, white matter hyperintensities, microbleed significance, and the "double hit" Alzheimer's co-pathology finding
• Coordination of the three-pillar intervention programme: pharmacy prescription management, cognitive training system access and onboarding, MIND diet counselling, and lifestyle modification support in English
• Plasma NfL monitoring coordination at 3-month intervals: blood draw scheduling, results translation, and communication with Dr. Ding's team for dynamic treatment adjustment
• MRI surveillance scheduling at 6 months: WMH volumetry and microbleed count comparison with baseline
• Acute stroke emergency coordination (Month 8): CMCS on-call team activated simultaneously with the stroke centre; family liaison maintained throughout the emergency thrombectomy procedure; real-time bilingual communication between Dr. Ding's team and Mr. Chen's family in the United States
• Post-stroke rehabilitation coordination: physiotherapy and speech therapy scheduling, anticoagulation monitoring, and communication with Mr. Chen's home neurologist for ongoing management

For international executives and expatriates in Shanghai, cognitive decline and stroke risk are frequently under-recognised and under-managed — dismissed as "stress" or "jet lag" until a catastrophic event occurs. CMCS exists to change that trajectory: connecting patients with Shanghai's leading neurologists for precision brain health assessment before symptoms become irreversible, and ensuring that when emergencies do occur, the response is immediate, coordinated, and fully supported in the patient's language.

This case report is de-identified and published for educational purposes. All clinical details have been anonymized in accordance with patient privacy standards. CMCS Shanghai is a medical concierge service and does not provide direct medical care.